Clinical trials: Nutrition Disorder
Overweight and Obesity
Web-based Weight Loss Intervention
Excess weight is a major risk factor underlying leading causes of death globally, including cardiovascular disease, type 2 diabetes, and some cancers.
- Trial name
- NCT03400696
- Testing
- Lower carbohydrate diet, Higher fiber diet, Physical activity focused
- Where
- 2 sites in United States
- Volunteers
- 63,656 people, healthy volunteers welcome
- Sponsor
- 23andMe, Inc.
Overweight (BMI > 25), Obesity & Overweight
Global Overweight and oBesE (GLOBE) Patient Registry, Development and Implementation of Disease-specific: Severity, Quality of Life and Cost Instruments.
We are conducting this study to develop a disease-specific instrument, a quality of life instrument and a comprehensive list of costs associated with overweight and obesity.
- Trial name
- GLOBE (NCT07229027)
- Where
- United Kingdom
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Medialis Ltd.
Obesity
Study of Weight-Reducing Effect and Safety of Rimonabant In Obesity in ASIA (RIO-ASIA)
Primary : effect on weight loss and weight maintenance over 9 months when prescribed with a hypocaloric diet in obese patients. Secondary : effect on HDL-Cholesterol, triglycerides, fasting-insulin, fasting glucose, waist…
- Trial name
- NCT00325546
- Testing
- Rimonabant (SR141716)
- Where
- 3 sites in China, South Korea and 1 more
- Volunteers
- 643 people
- Sponsor
- Sanofi
Pain, Postoperative, Postoperative Pain
Intraperitoneal Aerosolized Delivery of a Local Anesthetic for Post Operative Pain Management. A Double Blind, Randomised Controlled Clinical Trial.
The purpose of this study is to determine the effectiveness of aerosolized pain medication (.5% bupivicaine) delivered into the peritoneal cavity after laparoscopic gastric bypass surgery.
- Conditions
- Pain, Postoperative, Postoperative Pain, Abdominal Pain, Obesity
- Trial name
- NCT00286286
- Testing
- Intraperitoneal Aerosolization System, IntraMyst
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Northgate Technologies
NAFLD, Obesity
A Study to Evaluate the Safety and Effectiveness of Saroglitazar 4 mg in Patients With NAFLD With Comorbidities
A Phase 4, non-randomized, multicentre, open-label, single-arm study to evaluate the safety and efficacy of Saroglitazar 4 mg in patients with non-alcoholic fatty liver disease (NAFLD) with comorbidities (either obesity, type 2…
- Conditions
- NAFLD, Obesity, Type 2 Diabetes, Dyslipidemias
- Trial name
- NCT05872269
- Testing
- Saroglitazar
- Where
- 19 sites in India
- Volunteers
- 1,500 people
- Sponsor
- Zydus Lifesciences Limited
Hypertriglyceridemia, Obesity
Setmelanotide in a Single Patient With Partial Lipodystrophy
The objective of this single patient study is to assess the safety and efficacy of setmelanotide as a treatment of severe metabolic abnormalities resulting from LD, especially refractory hypertriglyceridemia leading to recurrent…
- Trial name
- NCT03262610
- Testing
- Setmelanotide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Type 2 Diabetes, Obesity
A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity
This is a multicenter, randomized, Open-label Phase 3 clinical study comparing the efficacy and safety of IBI362 6 mg OW versus Semalgutide 1 mg OW in obese(BMI≥28kg/m2) early T2D subjects.
- Trial name
- NCT06184568
- Testing
- IBI362, Semaglutide
- Where
- China
- Volunteers
- 349 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Obesity
First in Human Study in Subjects With Obesity, But Otherwise Healthy
This is a First in Human study to evaluate the safety and tolerability of DA-1726 following single and multiple doses in participants with obesity, but otherwise healthy subjects.
- Trial name
- NCT06252220
- Testing
- DA-1726
- Where
- United States
- Volunteers
- 139 people
- Sponsor
- NeuroBo Pharmaceuticals Inc.
Obesity, Overweight
A Trial of Oral VRB-103 Alone or in Combination With Oral Ecnoglutide (VRB-101) in Participants With Obesity or Overweight
The primary objective is to evaluate the safety and tolerability of VRB-103 tablets administered as monotherapy or VRB-103 tablets administered in combination with oral ecnoglutide tablets (VRB-101 tablets) in a single-dose…
- Trial name
- NCT07628127
- Testing
- VRB-103, VRB-101
- Where
- 3 sites in Australia
- Volunteers
- 332 people, healthy volunteers welcome
- Sponsor
- Verdiva Bio Dev Limited
Overweight and Obesity
An Evaluation of Omega-3 Fatty Acid
This protocol will determine the pK profile of two different omega-3 fatty acid supplements on plasma EPA and DHA levels.
- Trial name
- NCT03017651
- Testing
- OM3-supplement 1, OM3-supplement 2
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Obesity & Overweight
Spartina® (Tirzepatide) Effectiveness and Safety Evaluation
The goal of this study is to evaluate Effectiveness and safety of Spartina® (Tirzepatide) in male or female participants with obesity and overweight. The main questions which are aimed to be answered: 1.
- Trial name
- NCT07262762
- Where
- 14 sites in Iran
- Volunteers
- 175 people
- Sponsor
- Cinnagen
Obesity, Type 2 Diabetes Mellitus
Procedure for Duodenal-Ileal Diversion With a Sleeve Gastrectomy for Patients With Obesity and Type 2 Diabetes Mellitus
Study will monitor weight loss and metabolic indicators for subjects in multi-center, single arm trial.
- Trial name
- NCT04627103
- Testing
- Self Forming Magnetic (SFM) Anastomosis System
- Where
- 2 sites in Canada
- Volunteers
- 18 people
- Sponsor
- GI Windows, Inc.
Overweight
Possibilities of Recording Changes in Various Health Parameters by Measuring Bioimpedance With the mBCA 555 During the Use of Products From the L112 Product Range
As a combination of medical products (mBCA scale, mBCA standing aid, length measuring rod and cloud-based software), the seca mBCA 555 makes it possible to determine nutritional status, energy consumption and body water…
- Trial name
- MEGA L112 (NCT07495696)
- Testing
- formoline L112 EXTRA
- Where
- Germany
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Certmedica International GmbH
Obesity
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
This study has 2 parts: First part is the main study and second part is the extension study. During the main study participants will receive 1 of 4 study medicines.
- Trial name
- REDEFINE 1 (NCT05567796)
- Testing
- Cagrilintide, Semaglutide
- Where
- 256 sites in United States, Argentina and 21 more
- Volunteers
- 3,400 people
- Sponsor
- Novo Nordisk A/S
Sarcopenia in Elderly, Malnourished
The Effects of MediDrink Platinum+ and Fava Bean Protein Hydrolysate on Fitness in an Aged Population
Examining the effects of MediDrink Platinum+ containing novel protein blend SRP-01 alone or when combined with PeptiStrong on clinical responses in elderly adults with sarcopenia
- Conditions
- Sarcopenia in Elderly, Malnourished, Protein Supplementation, Muscle Mass
- Trial name
- NCT07322653
- Testing
- MediDrink Platinum+, MediDrink Platinum+ and PeptiStrong
- Where
- 2 sites in Hungary
- Volunteers
- 75 people
- Sponsor
- Nuritas Ltd
Obese, Obesity
Aleniglipron Phase 2 in Type 2 Diabetes Mellitus
The purpose of this study is to assess the safety and tolerability of aleniglipron at doses up to 180 mg once daily (QD) in participants with T2DM who are living with obesity (body mass index [BMI] ≥ 30 kg/m2) or overweight (BMI…
- Conditions
- Obese, Obesity, Obesity Type 2 Diabetes Mellitus, Weight Loss
- Trial name
- GSBR-1290 (NCT07400588)
- Testing
- Aleniglipron
- Where
- 16 sites in United States
- Volunteers
- 58 people
- Sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Overweight, Obesity
A Research Study Investigating NNC0247-0829 for Weight Management in People With Overweight or Obesity
This study looks at NNC0247-0829 (a potential new medicine) for weight management in people with overweight or obesity. The study looks at how NNC0247-0829 works in the body.
- Trial name
- NCT04010786
- Testing
- NNC0247-0829
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus (T2DM), Overweight or Obese
A Study of BGM0504 in Healthy Participants and Participants With Impaired Renal Function
The purpose of this study is to assess how fast BGM0504 gets into the blood stream and how long it takes the body to remove it in participants with impaired kidney function compared to healthy participants.
- Trial name
- NCT06929156
- Testing
- BGM0504
- Where
- China
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
Malnutrition
Nutrition Intervention in Older Adults at Risk of Malnutrition
Thailand is one of the fastest aging countries and older adults are at greater risk of having inadequate nutrient intake and malnutrition (undernutrition).
- Trial name
- NCT05682781
- Testing
- Oral Nutritional Supplement, Dietary Counseling
- Where
- 2 sites in Thailand
- Volunteers
- 196 people
- Sponsor
- Abbott Nutrition
Obesity
Transoral Gastroplasty for the Treatment of Morbid Obesity
The TOGA® trial is a prospective, multi-center, randomized sham-controlled trial designed to determine the safety and effectiveness of the TOGA System for the treatment of morbid obesity.
- Trial name
- TOGA® (NCT00661245)
- Testing
- TOGA, Control
- Where
- 11 sites in United States, Belgium
- Volunteers
- 275 people
- Sponsor
- Satiety, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.